Developing Herceptin was not without its challenges. Initial skepticism from the scientific community and pharmaceutical companies posed significant hurdles. Funding was also a major issue. However, Dr. Slamon's persistence and belief in the potential of targeted therapy eventually led to successful clinical trials and FDA approval in 1998.
